Editas Medicine Inc (EDIT) - News Archive

Editas Medicine, a pioneering company in the field of gene editing, presented significant advancements in their proprietary targeted lipid nanoparticle (LNP) delivery system at the European Hematology Association (EHA)...

Updated Insights into Reni-cel Therapy for Severe Sickle Cell Disease Presented at ASH Annual Meeting In a recent development at the 64th American Society of Hematology (ASH) Annual Meeting, Editas Medicine unveiled upd...

Editas Medicine: Navigating Financial Challenges while Pioneering Gene Editing SolutionsIn an ever-evolving biotechnology landscape, Editas Medicine Inc. is making strides both in clinical advancements and financial str...

Balancing Financial Strength Amidst Clinical AdvancementsIn the fast-evolving biotechnology landscape, Editas Medicine Inc. has made a significant move that not only fortifies its balance sheet but also sets the stage f...

In a groundbreaking achievement, Editas Medicine, a leading biotechnology company, presented new safety and efficacy data from the RUBY trial of Reni-cel at the prestigious European Hematology Association (EHA) Annual C...

Editas Medicine, a leading gene editing company, has recently announced exciting updates in the field of clinical trials. The company is set to present clinical data from the RUBY and EdiTHAL trials of reni-cel at the u...

Advancements in In Vivo Gene Editing Technologies Show Promise for Genetic MedicineGene editing has emerged as a groundbreaking field in biomedical research, offering potential solutions for a range of genetic disorders...

In a promising stride towards developing innovative therapies for cancer and autoimmune diseases, Editas Medicine and Bristol Myers Squibb (BMS) have announced a two-year extension of their collaboration on the research...

Editas Medicine, a leading gene editing company, and Vertex Pharmaceuticals, a renowned biotechnology company, have announced their collaboration through a non-exclusive license agreement for Cas9. The license will spec...

:Editas Medicine, a renowned biotechnology company focused on developing transformative genome editing treatments, has recently shared groundbreaking safety and efficacy data for their innovative therapy, EDIT-301. Thes...